主持国家重点研发计划干细胞及转化研究重点专项（首席科学家）、国家自然科学基金（7项）、国家重点研发计划发育编程及其代谢调节重点专项PI、上海市科委重大课题、江西省自然基金重点项目等30余项课题，累计经费13255万元。发表论文117篇，其中SCI论文90篇，总影响因子750。以第一作者或通讯作者（含共同）发表SCI论文56篇，总影响因子482，43篇大于5，24篇影响大于10，其中4篇影响因子大于20。申请专利26项，其中12项已授权，国际PCT专利1项。参加专著和国家统编教材编写13部，承担教学课题和学生创新指导课题11项。研究成果被评为中国科学十大进展、细胞出版社中国年度论文、上海市优秀发明金奖、上海医学科技奖等。研发和推动多个干细胞治疗新药临床注册研究或干细胞临床备案研究。

1．P21阳性衰老肝细胞诱导肝脏炎症性衰老的作用与机制研究，国家自然科学基金面上项目（82471592，48万），2025.1.1-2028.12.31

2．何志颖，惠利健。“再生医学”学科发展规划，5万，2023 年 6 月-2023 年10 月，2023 年度中国细胞生物学学会/上海市创新细胞生物学发展基金会中国细胞生物学学会学科发展研究。

3．应用谱系示踪技术研究肝细胞衰老在肝癌发生和防治中的作用与机制，江西省自然科学基金重点项目（20212ACB206033，20万），2021.07.01-2025.06.30。

4．干细胞治疗帕金森病，干细胞转化医学团队，长宁区第五轮后备创新团队（2021-2023年），9万。

5．应用谱系示踪技术研究诱导细胞衰老在肝癌防治中的作用和机制，国家自然科学基金面上项目（82173019，54.7万），2022.1.1-2025.12.31。

6．干细胞与转化（第二轮），上海高校Ⅳ类高峰学科，子课题负责人。170万，2023.01-2025.12。

7．上海干细胞转化医学工程技术研究中心，上海市2020年度“科技创新行动计划”，20DZ2255100，2020.12.01-2022.11.30，3319.45万元。

8．国家重点研发计划“干细胞及转化研究重点专项”，2020YFA0112600，干细胞治疗产品的规范化与规模化生产及质量评价研究，2020.10-2024.12，7926万，在研，主持。

9．上海市2020年度“科技创新行动计划”学术/技术带头人项目，功能纳米材料促进肝细胞移植再生肝脏，20XD1434000，2020.10.1-2023.09.30，40万。

10．   再生医学学科规划，教育部高等学校科技规划学科前沿课题，2020.7-2020.12，5万，协调、联络、起草。

11．   细胞移植与组织再生，同济大学中青年科技领军人才，2020.1.1-2021.12.31，40万。

12．   重要实质性脏器的细胞更替和调控机制，2019YFA0801500，2653万元。（课题二：应激和老化过程中心脏和肝脏的细胞协调作用与更新替换机制，2019YFA0801502），国家重点研发计划“发育编程及其代谢调节”重点专项 （2019），2019.12-2024.11，骨干/PI，236万。

国家重点研发计划“发育编程及其代谢调节”重点专项，2019YFA0801502，应激和老化过程中心脏和肝脏的细胞协调作用与更新替换机制， 2019.12-2014.11，236万，在研，PI。

13．   上海干细胞产业发展战略研究，中国工程科技发展战略上海研究院战略咨询项目，省部级软课题项目，100万元，骨干。

14．   上海市老年疾病临床医学研究中心，19MC1910500，复旦大学附属华山医院徐文东，上海市临床医学研究中心（第一批）项目，上海市科委，500万（单位1：1匹配）。“干细胞治疗老年衰弱及其并发症的临床研究”课题的基础PI。

15．   干细胞抗辐射技术的转化研究及其在东海核应急医学救援体系中的应用，上海市军民融合发展专项项目，2019-jmrh1-kj51，2019.07-2021.12。240万，执行负责人/子课题负责人。the specific fund forShanghai military-civilian integration and development (2019-jmrh1-kj51)

16．   慢性肝损伤诱导肝癌发生中示踪衰老肝细胞生物学行为的动物模型的建立，上海市科委“科技创新行动计划”实验动物研究项目，19140902900，30万元，2019.05.01-2023.04.30。

17．   干细胞体内命运转归研究平台建设负责人，2019年5月18日，上海市发展和改革委员会2019年（第1批）确定的上海市工程研究中心：上海市干细胞临床诊疗工程研究中心

18．   消化疾病学科，PWYgf2018-04，2018-11-1至2021-10-31，浦东新区卫生健康委员会临床高峰学科建设，PI，4000万元（其中2000万元自筹） 。

19．   上海张江国家自主创新示范区干细胞战略库与干细胞技术临床转化平台，上海张江国家自主创新示范区专项发展资金重大项目，ZJ2018-ZD-004，2018年07月01日--2020年12月31日，干细胞共性技术研发平台负责人（首次经费200万），2.5676亿（专项1.2485亿）。

20．  干细胞与转化，上海高校Ⅳ类高峰学科，团队骨干（B岗）。5000万，2018.10-2020.12。

21．  基于磁光声效应功能纳米材料促进肝细胞移植再殖肝脏的研究，中央高校基本科研业务费专项资金资助（22120180423，5万），2018.9-2019. 8。（Supported by the Fundamental Research Funds for the CentralUniversities）

22．  人脐带来源间充质干细胞的制备及临床前研究，上海市科委重大课题（17431906600，1000万），2017.12.01-2020.12.30。执行负责人，子课题负责人（排名第3）。Key Project of ShanghaiScience and Technology Committee (17431906600)

23．  谱系重编程肝干细胞治疗肝衰竭的应用研究，上海市浦东新区科技发展基金民生科研专项资金医疗卫生项目（PKJ2017-Y16，20万），2017.11.1-2020.10.31。

24．  慢性肝损伤诱导的细胞衰老抑制促进肝癌发生的作用和机制，国家自然科学基金面上项目（81772954，55万），2018.1.1-2021.12.31。

25．  谱系重编程获得人肝干细胞及其治疗肝衰竭的应用研究，上海市浦江人才计划（17PJD045，20万）, 2017.9.1-2019.8.31。

26．  不同来源肝干细胞的获得及其开展肝衰竭治疗的研究，上海市东方医院引进人才科研启动基金（DFRC2017011，100万），2017.7.1-2022.6.31。

27．  "Engineering Stem Cells for Future Therapy". Pennsylvania Department of Health（GrantAgreement SAP #4100068730）,$120,000(total $600,000/500K direct + 100K indirect), 2015.9.1-2018.12.31。

28．  应用谱系重编程技术获得人肝系细胞建立肝炎病毒感染的人源化小鼠模型，国家自然科学基金面上项目疾病动物模型专项(81471948，170万)，2015.1-2018.12。

29．  肝细胞的衰老机制及衰老逆转的研究，国家自然科学基金面上项目(31271474，80万)，2013.1-2016.12.

30．  组织干细胞在器官衰老与再生中的作用及调控机制研究(2011CB966200)，国家重点基础研究发展计划，100万，2011.1-2015.12，PI。(首席张雁云)。

31．  染色质重排因子Smarca2介导的肝再生负向调控作用的研究，国家自然基金（10万，第二，合作申请/合作单位负责人），31100996，23万，2012.1-2014.12。

32．  细胞周期因子FoxM1促进肝脏再殖的研究。国家自然科学基金（30801115，21万）。2009.1-2011.12。

33．  SB转座子介导MMPs/TIMPs基因治疗肝纤维化的研究（30901449）。国家自然科学基金（22万）。2010.1-2012.12。

34．  FAH基因剔除小鼠肝纤维化的细胞治疗。中国博士后科学基金（20070410743，3万）。2007.5-2009.10。

35．  胚胎干细胞肝向特定分化阶段细胞其肝脏再殖特性的研究。中国科学院上海生命科学研究院生物化学与细胞生物学研究所博士后基金（6万）。2006.10-2009.10。

36．  小体积活体肝移植结合辅助性肝细胞移植的临床实验研究（07JC14067）。上海市科委计划项目（40万），合作申请/子课题负责人，2007.10-2009.10。

2025年 （待续）

1.     Xuejing Zhu, LeiZhang, Wenqian Cui, Liangjie Wang, Fengjing Xu, Mengyuan Liu, Shuangcheng Chen,Haowen Jiang, Zhiying He*, Chang Peng* and Jinlong Li*,Unveiling p65 as the target of diphyllin in ameliorating metabolicdysfunction-associated steatotic liver disease via targeted protein degradationtechnology. Frontiers in Pharmacology-TranslationalPharmacology, 2025 accepted. (IF: 4.4)

2.    Liu WM#, Chen CY#, Ma HQ#, Zhang QQ, Zhou X, WuYL, Huang WJ, Qi XS, Zhang YX, Tang D, Sun HY, WuHP, Jiao TF, He ZY*, Yu WF*, Yan HX*. Inhibition of liver cancer cell growth by metabolitesS-adenosylmethionine and nicotinic acid originating from liver progenitor cells. Journal ofGastroenterology 2025.https://doi.org/10.1007/s00535-025-02226-y. (IF: 6.9)

3.    Tian J#, Hao WP#, Li J, Na XM, Wang S,Wei W, Lu YF, Cui YY, Zhang WC, He ZY*, Ma GH*, Zhou WQ*. Microcarrier stiffness controlshuman amniotic epithelial cells (hAECs) proliferation andepithelial-mesenchymal transition (EMT) via remodeling ECM and Wnt/ß-cateninpathway. Chemical Engineering Journal 2025; Available online. *Corresponding authors. (IF: 13.3)

4.     Mu XL, Pan LL, Wang XC, Liu CC, Li Y, Cai YC*, He ZY*. Development of a prognostic model for hepatocellular carcinoma basedon microvascular invasion characteristic genes by spatial transcriptomicssequencing. Frontiers in lmmunology 2025; 16:1529569. doi: 10.3389/fimmu.2025.1529569. *Correspondingauthors. (IF: 5.7)

5.     Ye HJ, Wang XC, He ZY*. Identification of mitophagy-related biomarkers and immune infiltrationin polycystic ovarian syndrome by bioinformatic study. Heliyon 2025; Available online 23 January 2025,e42202. *Corresponding author. (IF: 3.4)

6.     Hao WP#, Luo Y#, Tian J#, Lu YF#, Cui YY, Zhang Y, Jin X, Ye HJ, Lu MQ,Song JJ, Zhou WQ*, Zhang WC*, He ZY*. Scale-up of Human Amniotic Epithelial Cells through Regulation of Epithelial-MesenchymalPlasticity under Defined Conditions. AdvancedScience, 2025 Jan 13: e2408581. doi:10.1002/advs.202408581. *Corresponding authors. (IF: 15.1)

2024年

1.     Lu JZ, Zhang L, Cao HX, Ma XX, Bai ZH, Zhu HY, Qi YY, Zhang SM, Zhang P, He ZY, Yang HT, Liu ZM, Jia WW. The LowTumorigenic Risk and Subtypes of Cardiomyocytes Derived from Human-inducedPluripotent Stem Cells. Current StemCell Research &Therapy (2024) (IF: 3.758)

2.     Song JJ#, Lu MQ#, He ZY*, Zhang WC*. Models of Fibrolamellar Carcinomas, Tools for Evaluation ofa New Era of Treatments. Frontiers in lmmunology 2024 Nov 8:15:1459942. doi: 10.3389/fimmu.2024.1459942. *Correspondingauthors. (IF: 5.7)

3.     Yang J#, Lu YF#, Zhao JP#, Luo Y#, Hao WP, Zhang WC *, He ZY*. Reinvesting the Cellular Properties of Human Amniotic Epithelial Cellsand Their Therapeutic Innovations. Frontiers in lmmunology 2024; Oct 15: 15:1466529. doi: 10.3389/fimmu.2024.1466529. *Correspondingauthors. (IF: 5.7)

4.     Chen MM#, Chen WJ#, Sun SW#, Lu YL, Wu GX, Xu HY, Yang HR, Li C, He WZ,Xu MY, Li XH, Jiang D, Cai YC, Liu CC, Zhang WC, He ZY*. CDK4/6 inhibitor PD-0332991suppresses hepatocarcinogenesis by inducing senescence of hepatictumor-initiating cells. Journal ofAdvanced Research 2024; S2090-1232(24)00374-6. *Corresponding author. (IF: 11.4)

5.     Zhang WC#*, Cui YY#, Lu MQ#, Xu MY#, Li YT#, Song HM, Luo Y, Song JY,Yang Y, Wang XC, Liao LJ, Wang YF, Lola Reid*, He ZY*. Hormonally and ChemicallyDefined Expansion Conditions for Organoids of Biliary Tree Stem Cells. Bioactive Materials 2024; 41:672-695. *Correspondingauthor. (IF: 18)

6.     Chen F, Zhang KS, Wang MJ, He ZY, Yu B, Wang X, PanXH, Luo YP, Xu SJ, Lau JTY, Han CS, Shi YF, Sun YE, LiSG, Hu YP. VEGF-FGF Signaling Activates Quiescent CD63+ Liver StemCells to Proliferate and Differentiate. AdvSci (Weinh). 2024 Jun 17: e2308711. oi:10.1002/advs.202308711. (IF: 14.3)

7.     Qi YY#, Wang XC#, Bai ZH#, Xu Y, Lu TT, Zhu HY, Zhang SM, Wu ZH, Liu ZM*,He ZY*, Jia WW*. Enhancement of the function of mesenchymal stem cells by usinga GMP-grade three-dimensional hypoxic large-scale production system. Heliyon 2024; 10(10), E30968. Published on May17, DOI: https: //doi.org/10.1016/j.heliyon.2024.e30968. *Corresponding authors. (IF: 3.4)

8.     Wang Y#, Yuan T#, Lyu T, Zhang L, Wang M, He ZY*, Wang Y*, Li Z*. Mechanism of inflammatory response and therapeuticeffects of stem cell in ischemic stroke: Current evidence and futureperspectives. Neural Regeneration Research 2025, 20(1): 67-81. *Correspondingauthors. (IF: 5.9)

9.     Chen MM#, Wu GX#, Lu YL#, Sun SW, Yu Z, PanX, Chen WJ, Xu HY, Qiu H, He WZ, Li XH, Wang XC, Luo Y, Du Y, Wu JL, Wei K,Zhang WC, Liu ZM, He ZY *. A p21-ATD Mouse Model for Monitoringand Eliminating Senescent Cells and Its Application in Liver Regeneration postInjury. Molecular Therapy 2024; Apr 6: S1525-0016(24)00218-1. doi: 10.1016/j.ymthe.2024.04.002. *Corresponding author. (IF:12.1)

10. Shen SW#, Zhang WC#,Xu C#, Dong ZX, Wang XC, Liu CC, Lu FF, Hu YH, Tang QH*, Cheng Y*, He ZY*. Magnetotactic hepatocytes promote liverrepopulation after transplantation. ChemicalEngineering Journal 2024; 486, 150278. *Correspondingauthors. (IF: 13.3)

11.  Wang XC#, Yang C#, Ma XX#, Li XH, Qi YY, Bai ZH, Xu Y,Ma KM, Luo Y, Song JY, Jia WW*, He ZY*, Liu ZM*. Adivision-of-labor mode contributes to thecardioprotective potentia of mesenchyma stem/stromal cells in heart failurepost myocardiainfarction. Frontiersin lmmunology 2024; 15: 1363517. *Correspondingauthors. (IF: 5.7)

12. Aging Biomarker Consortium, Jiang MM#,Zheng ZZ#, Wang X#，Chen YH#，Qu J*，Ding QR*，Zhang WQ*，Liu YS*，Yang JC*，Tang WQ*，Hou YL*，He JH*，Wang L*，Huang PY*，Li LC*，He ZY*，Gao Q*，Lu Q*，Wei L*，Wang YJ*，Ju ZY*，Fan JG*，Ruan XZ*，Guan YF*，Liu GH*，Pei G*，Li J*，Wang YF*. A biomarker framework for liver aging: the Aging BiomarkerConsortium consensus statement. LifeMedicine 2024, lnae004. *Corresponding authors.

13. He WZ#, Wang XC#,Chen MM#, Li C, Chen WJ, Pan LL, Cui YY, Yu Z, Wu GX, Yang Y, Xu MY,Dong ZX, Ma KM, Wang JH, He ZY*. Metformin reduces hepatocarcinogenesisby inducing downregulation of Cyp26a1 and CD8+ T cells. Clinical and Translational Medicine,2023; 13(11): e1465. *Correspondingauthor.  (IF: 10.60)  

14.  WangL, Liu S, Li K, Ma A, Hu C, Wang C, Cao N, Zhao Y, Fu R, Jia W, Xiang P, Liu H,Qi Z, Zhu N, Liang L, Wang L, Cao J, Zhai P, Zhou J, Wei J, Na T, Wu J, HeZ, Zhou G, Yu W, Wu J, Zeng W, Zhang Y, Zhu L, Fu B, Zhang J, Yang S,Dai C, Cui H, Jing J, Yan H, He X, Lu Y, Tong C, Zhao T, Hao J, Liu X, Jin Y,Wang Y. General requirements forthe production of extracellular vesicles derived from human stem cells.Cell Prolif. 2024 Mar; 57(3):e13554. (IF: 5.9)

2023年

1. He WZ#, Wang XC#, Chen MM#, Li C, Chen WJ, Pan LL, Cui YY, Yu Z, Wu GX, Yang Y, Xu MY, Dong ZX, Ma KM, Wang JH, He ZY*. Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells. Clinical and Translational Medicine, 2023; 13(11): e1465. *Corresponding author.  (IF: 10.60，中科院1区)  

2. Zhang WC#, Xu YM#, Wang CX#, Oikawa T, Su GW, Wauthier E, Wu GX, Sethupathy P, He ZY*, Liu L*, Reid LM*. Fibrolamellar Carcinomas Growth arrested by paracrine signals complexed with synthesized 3-O sulfated heparan sulfate oligosaccharides. Matrix Biology 2023; 121: 194-216. *Corresponding authors. (IF: 6.9，中科院1区)

3. Zhang WC#, Cui YY#, Du Y#, Yang Y#, Fang T#, Lu FF, Kong WX, Xiao CJ, Shi J, Reid LM*, He ZY*. Liver Cell Therapies: Cellular Sources and Grafting Strategies. Frontiers of Medicine 2023; 17(3): 432-457. *Corresponding authors. (IF: 8.1)

4. Zhang WC#, Wang XC#, Lanzoni G, Wauthier E, Simpson S, Ezzell JA, Allen A, Suitt C, Krolik J, Jhirad A, Dominguez-Bendala J, Cardinale V, Alvaro D, Overi D, Gaudio E, Sethupathy P*, Carpino G*, Adin C*, Piedrahita JA*, Mathews K, He ZY*, Reid LM*. A postnatal network of co-hepato/pancreatic stem/progenitors in the biliary trees of pigs and humans. NPJ Regenerative Medicine 2023; 8(1): 40. *Corresponding authors. (IF: 7.2，中科院1区) 

5. Yang Y#, Zhang W#, Wang X, Yang J, Cui Y, Song H, Li W, Li W, Wu L, Du Y, He ZY*, Shi J*, Zhang J*. A passage-dependent network for estimating the in vitro senescence of mesenchymal stromal/stem cells using microarray, bulk and single cell RNA sequencing. Frontiers in Cell and Developmental Biology. 2023; 11: 998666. *Corresponding authors. (IF: 5.5)

2022年

1. Chen WJ, Zhang WC, Chen MM, Yang C, Fang T, Wang HF, Reid LM, He ZY*. Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumors. Cell Oncol (Dordr). 2022; 45(6): 1053-1071. *Corresponding author. (IF: 6.6)

2. Zhang WC, Carpino G, Wangensteen KJ, Yan HX, He ZY. Editorial: Cell therapy, liver diseases, and regeneration. Frontiers in Cell and Developmental Biology 2022; 10:999305. 

3. Zhang WC, Wauthier E, Lanzoni G, Hani H, Yi XW, Overi D, Shi L, Simpson S, Allen A, Suitt C, Ezzell JA, Alvaro D, Cardinale V, Gaudio E, Carpino G, Prestwich G, Dominguez-Bendala J, Gerber D, Matthews K, Piedrahita J, Adin C, Sethupathy P*, He ZY*, Reid LM*. Patch grafting of organoids of stem/progenitors into solid organs can correct genetic-based disease states. Biomaterials 2022; 288: 121647.  *Corresponding authors. (IF: 14，中科院1区)

4. Liu P, Wang XJ, Pan LL, Han B*, He ZY*. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis. Frontiers in Immunology 2022; 901784. *Corresponding authors. (IF: 8.786).

5. Du Y, Zhang WC, Qiu H, Xiao CJ, Shi J, Reid LM, He ZY*. Mouse Models of Liver Parenchyma Injuries and Regeneration. Frontiers in Cell and Developmental Biology 2022; 10: 903740. *Corresponding author. (IF: 6.081)

6. Zhang WC, Lou YR, Zhou JJ, He ZY. Editorial: Stem Cells in Tissue Homeostasis and Disease. Frontiers in Cell and Developmental Biology 2022; 10: 876060.7. Cai YC#, Fu Y#, Liu CC#, Wang XC#, You P, Li XH, Song YX, Mu XN, Jiang D, Yang Y, Gu YY, Zhang HB*, He ZY*. Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma. Cell Death & Disease 2022; 13(2): 176. *Corresponding authors. (IF: 9).

2021年

1. Zhang WC, Lanzoni G, Hani H, Diletta O, Cardinale V, Simpson S, Pitman W, Allen A, Yi XW, Wang XC, Gerber D, Prestwich G, Lozoya O, Gaudio E, Alvaro D, Tokaz D, Dominguez-Bendala J, Adin C, Piedrahita J, Matthews K, Sethupathy P*, Carpino G, He ZY*, Wauthier E*, Reid LM*. Patch Grafting, Strategies for Transplantation of Organoids into Solid Organs such as Liver. Biomaterials 2021; 277:121067. *Corresponding authors. (IF: 15.304，中科院1区)

2. Lu FF#, Pan X#, Zhang WC#, Su X, Gu YY, Qiu H, Shen SW, Liu CC, Liu W, Zhan ZZ, Liu ZM*, He ZY*. A Three-dimensional Imaging Method for the Quantification and Localization of Dynamic Cell Tracking Post-transplantation. Frontiers in Cell and Developmental Biology 2021; 9: 698795. *Corresponding authors. (IF: 6.081)

3. Wang SS#, Jiang K#, Du XY, Lu YL, Liao LJ, He ZY*, He WZ*. Translational Attenuation Mechanism of ErmB Induction by Erythromycin Is Dependent on Two Leader Peptides. Frontiers in Microbiology 2021; 12: 609711. *Corresponding authors. (IF: 6.064)

4. Wang XC#, Zhang WC#, Yang Y, Wang JS, Qiu H, Liao LJ, Oikawa T, Wauthier E, Sethupathy P, Reid LM, Liu ZM*, He ZY*. A MicroRNA-Based Network Provides Potential Predictive Signatures and Reveals the Crucial Role of PI3K/AKT Signaling for Hepatic Lineage Maturation. Frontiers in Cell and Developmental Biology 2021; 9: 670059. *Corresponding authors. (IF: 6.081). 

2020年

1. Liu P#, Tang QH#, Chen MM, Chen WJ, Lu YL, Liu ZM*, He ZY*. Hepatocellular senescence: immunosurveillance and future senescence-induced therapy in hepatocellular carcinoma. Frontiers in Oncology 2020; 10: 589908. *Corresponding authors.  (IF: 6.244).

2. Liu W#, Liu Q#, Zhang BL, Lin ZB, Li X, Yang XS, Pu M, Zou RZ, He ZY*, Wang F*, Dou KF*. The mRNA of TCTP functions as a sponge to maintain homeostasis of TCTP protein levels in hepatocellular carcinoma. Cell Death & Disease 2020; 11(11): 974. *Corresponding authors.  (IF: 8.469).

2019年

1. Lu ZF#*, Li XH#, Xu YF, Chen MM, Chen W, Chen T, Tang QH*, He ZY*. microRNA-17 functions as an oncogene by down-regulating Smad3 expression in hepatocellular carcinoma. Cell Death & Disease 2019; 10(10):723. *Corresponding authors. (IF: 6.304).

2. Fu YB, He ZY*, Zhang C*. Advances of Stem Cell Therapy to Treat Heart Failure. Nano Life 2019; 9(3): 1941002. *Corresponding authors.

3. Cheng Z#, He ZY#, Cai YC#, Zhang C#, Fu GB, Li HY, Sun W, Liu CC, Cui XL, Ning BF, Xiang DM, Zhou TF, Li XF, Xie WF, Wang HY*, Ding J*.  Conversion of hepatoma cells to hepatocyte-like cells by defined hepatocyte nuclear factors. Cell Research 2019; 29(2): 124-135. #Co-first authors. (IF: 20.507，中科院1区).

4. Fu GB#, Zhou X#, Zeng M#, Huang WJ#, Wu HP#, Liu CC, Wu H, Weng J, Zhang HD, Cai YC, Ashton C, Ding M, Tang D, Zhang BH, Gao Y, Yu WF, Zhai B*, He ZY*, Wang HY*, Yan HY*. Expansion and differentiation of human hepatocyte-derived liver progenitor-like cells for the study of hepatotropic pathogen. Cell Research 2019; 29(1): 8-22. *Corresponding authors. (IF: 20.507，中科院1区).

2018年

1. Li XH#, Yang Y#, Liu W, Chen WJ, Hu KY, Wang WY, Wang C, Wu YF, Liu ZM*, He ZY*. Nanomaterials in liver regeneration: the prospect for application. Nano Life 2018; 8(4): 1841005. *Corresponding authors.

2. Yang Y#, Li XH#, Liu W, Chen JW, Liu CC, Cai YC, Song YX, Tang QH, Zhang C*, He ZY*. Generation of hepatocyte-like cells by different strategies for liver regeneration. Nano Life 2018; 8(4): 1841004. *Corresponding authors. 

3. Wang C#, Chen WJ#, You P#, Wu YF#, Zheng SY, Liu CC, Xiang D，Wang MJ#, Cai YC, Zhao QH, Borjigin U, Liu W, Xiong WJ, Wangensteen KJ, Wang X, Liu ZM*, He ZY*. The extent of liver injury determines hepatocyte fate toward senescence or cancer. Cell Death & Disease 2018; 9(5): 575. *Corresponding authors. (IF: 5.959).

4. Wang MJ#, Chen F#, Liu QG#, Liu CC, Yao H, Yu B, Zhang HB, Yan HX, Ye YB, Chen T, Wangensteen KJ, Wang X, Hu YP*, He ZY*. Insulin-like growth factor 2 is a key mitogen driving liver repopulation in mice. Cell Death & Disease 2018; 9(2): 26. *Corresponding authors. (IF: 5.959).

5. Xiao MC#, Chen WJ#, Wang C#, Wu YF, Zhu SW, Zeng CY, Cai YC, Liu CC, He ZY*. Senescence and cell death in chronic liver injury: roles and mechanisms underlying hepatocarcinogenesis. Oncotarget 2017; 9(9): 8772-8784. *Corresponding author. (IF: 5.168).

2017年及之前

1. Wu H#, Zhou X#, Fu GB#, He ZY#, Wu HP#, You P, Ashton C, Wang X, Wang HY, Yan HY. Reversible transition between hepatocytes and liver progenitors for in vitro hepatocyte expansion. Cell Research 2017; 27(5): 709-712. #Co-first authors. (IF: 15.606，中科院1区).

2. Zhao H#, He ZY#, Huang DD, Gao J, Gong YF, Wu HY, Xu AF, Meng XJ, Li ZS. Infusion of bone marrow mesenchymal stem cells attenuates experimental severe acute pancreatitis in rats. Stem Cells International 2016; 2016: 7174319. #Co-first authors. (IF: 3.540).

3. Xiang D#, Liu CC#, Wang MJ#, Li JX, Chen F, Yao H, Yu B, Lu L, Borjigin U, Zhong L, Wangensteen KJ, He ZY*, Wang X*, Hu YP*. Non-viral FoxM1 gene delivery to hepatocytes enhances liver repopulation. Cell Death & Disease 2014; 5(5): e1252. *Corresponding authors. (IF: 5.014). 

4. Wang MJ#, Chen F#, Li JX, Liu CC, ZhangHB, Xia Y, Yu B, You P, Xiang D, Lu L, Yao H, Borjigin U, Yang GS, Wangensteen KJ, He ZY*, Wang X*, Hu YP*. Reversal of hepatocytes senescence after continuous in vivo cell proliferation. Hepatology 2014, 60(1):349-61. *Corresponding authors. (IF: 11.055，中科院1区). 

5. Huang PY#, Zhang LD#, Gao YM#, He ZY#, Yao D, Wu ZT, Cen J, Chen XT, Liu CC, Hu YP, Lai DM, Hu ZL, Chen L, Zhang Y, Cheng X, Ma XJ, Pan GY, Wang X, Hui LJ. Direct reprogramming of human fibroblasts to functional and expandable hepatocyte cells. Cell Stem Cell 2014; 14(3): 370-84. #Co-first authors. (IF: 22.268，中科院1区). 

6. Yu B#, He ZY#, You P, Han QW, Xiang D, Chen F, Wang MJ, Liu CC, Lin XW, Borjigin U, Zi XY, Li JX, Zhu HY, Li WL, Han CS, Wangensteen KJ, Shi YF, Hui LJ, Wang X, Hu YP. Reprogramming fibroblasts into bipotential hepatic stem cells by defined factors. Cell Stem Cell 2013; 13(3): 328-340. #Co-first authors. (IF: 22.151，中科院1区). 

7. Deng L#, Ke X#, He ZY#, Yang D, Gong H, Zhang Y, Jing X, Yao J, Chen J. A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer. International Journal of Nanomedicine 2012; 7: 5053–5065. #Co-first authors. (IF: 3.463).

8. He ZY, Deng L, Li YF, Xiang D, Hu JK, Chen YX, Wang MJ, Chen F, Liu CC, Li WL, Zi XY, Wu X, Li GP, Wangensteen KJ, Hu YP, Wang X. Murine Embryonic Stem Cell-derived Hepatocytes Correct Metabolic Liver Disease after Serial Liver Repopulation. The International Journal of Biochemistry & Cell Biology 2012; 44(4): 648-58. (IF: 4.152)

9. Huang PY, He ZY, Ji SY, Sun HW, Xiang D, Liu CC, Hu YP, Wang X, Hui LJ. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 2011; 475: 386-389. (IF: 36.280，中科院1区)

10. Su BL#, Liu CC#, Xiang D, Zhang HB, Yuan SM, Wang MJ, Chen F, Zhu HY, He ZY*, Wang X, Hu YP*. Xeno-liver repopulation of human hepatocyte in Fah-/-Nod/Scid mice. Sci China Life Sci 2011; 54(3): 227-234. *Corresponding authors. (IF: 2.024)

11. Li FM#, He ZY#, Li YF, Liu PY, Chen F, Wang MJ, Zhu HY, Ding XY, Wangensteen KJ, Hu YP, Wang X. Combined Activin A/LiCl/Noggin treatment improves production of mouse embryonic stem cell-derived definitive endoderm cells. Journal of Cellular Biochemistry 2011; 112(4): 1022-34. #Co-first authors. (IF: 2.868).

12. Li FM, Liu PY, Liu CC, Xiang D, Deng L, Li WL, Wangensteen KJ, Song JG, Ma Y, Hui LJ, Wei LX, Li LS, Ding XY, Hu YP, He ZY*, Wang X*. Hepatoblast-like progenitor cells derived from embryonic stem cells can repopulate livers of mice. Gastroenterology 2010; 139(6): 2158-2169.e8. *Corresponding authors. (IF: 12.032，中科院1区)

13. He ZY, Zhang HB, Zhang X, Xie DF, Chen YX, Wangensteen KJ, Ekker SC, Firpo M, Liu CC, Xiang D, Zi XY, Hui LJ, Yang GS, Ding XY, Hu YP, Wang X. Liver Xeno-Repopulation with Human Hepatocytes in Fah-/-Rag2-/- Mice after Pharmacological Immunosuppression. American Journal of Pathology 2010; 177(3): 1311-9. (IF: 5.224)